» Articles » PMID: 39924616

Gefitinib Induces Apoptosis in Caco-2 Cells Via ER Stress-mediated Mitochondrial Pathways and the IRE1α/JNK/p38 MAPK Signaling Axis

Overview
Journal Med Oncol
Publisher Springer
Date 2025 Feb 9
PMID 39924616
Authors
Affiliations
Soon will be listed here.
Abstract

Gefitinib, a selective EGFR-tyrosine kinase inhibitor, exhibits potent cytotoxic effects on colorectal cancer cells, though its precise mechanisms are not fully understood. In this study, we demonstrated that gefitinib induces a dose-dependent cytotoxic response in Caco-2 cells, characterized by disrupted microtubule networks, impaired migration, and reduced viability. Gefitinib triggered apoptosis, as indicated by increased levels of cleaved caspase-3, PARP, and elevated late apoptosis rates. Mechanistically, gefitinib-induced endoplasmic reticulum (ER) stress, marked by the upregulation of IRE1α, CHOP, and ATF4. ER stress inhibition by 4-PBA significantly reduced apoptosis and restored mitochondrial membrane potential (MMP). Additionally, gefitinib-induced apoptosis was mediated through the mitochondrial pathway, reflected by the modulation of Bcl-2 family proteins, including the upregulation of Bax and Bim. Inhibition of the IRE1α-mediated JNK/p38 MAPK pathway further mitigated gefitinib-induced apoptosis and restored MMP. These findings highlight the critical role of ER stress and the IRE1α-JNK/p38 MAPK axis in gefitinib-induced mitochondrial apoptosis, offering potential therapeutic targets for colorectal cancer.

References
1.
Guo Y, Wang S, Zhao Z, Li J, Shang A, Li D . Skeletal muscle metastasis with bone metaplasia from colon cancer: A case report and review of the literature. World J Clin Cases. 2021; 9(30):9285-9294. PMC: 8567510. DOI: 10.12998/wjcc.v9.i30.9285. View

2.
Jung G, Hernandez-Illan E, Moreira L, Balaguer F, Goel A . Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020; 17(2):111-130. PMC: 7228650. DOI: 10.1038/s41575-019-0230-y. View

3.
Xie Y, Chen Y, Fang J . Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22. PMC: 7082344. DOI: 10.1038/s41392-020-0116-z. View

4.
Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Takeda K . Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003; 14(6):922-30. DOI: 10.1093/annonc/mdg250. View

5.
Frederick B, Helfrich B, Coldren C, Zheng D, Chan D, Bunn Jr P . Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007; 6(6):1683-91. DOI: 10.1158/1535-7163.MCT-07-0138. View